Laverock Therapeutics, a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, has been awarded two new grants totalling in excess of £2.2m to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

The first grant-funded project will focus on scaling the company’s platform within a T-cell product context, utilising solid tumour-based patient datasets, and foundational data around both intracellular signalling and antigen expression. Leveraging single cell and AI-powered approaches Laverock will be able to rapidly identify the preferred combination of product features to unlock efficacy and safety in solid tumour cancer indications, tailored to tumour type, and using patient derived models for rapid prototyping and evaluation.

The second grant will enable the expansion of Laverock’s macrophage-based programmes into non-oncology indications, building upon the platform’s ability to program myeloid cell phenotypes and precisely control the expression of therapeutically relevant payloads. This work will be part of a consortium effort pulling in leading experts in the disease indication of interest and across the product development workflow to enable rapid translation to the clinic.